• Refine Query
  • Source
  • Publication year
  • to
  • Language
  • 5
  • 4
  • 2
  • 2
  • 2
  • Tagged with
  • 17
  • 17
  • 9
  • 4
  • 4
  • 4
  • 3
  • 3
  • 3
  • 3
  • 3
  • 3
  • 3
  • 2
  • 2
  • About
  • The Global ETD Search service is a free service for researchers to find electronic theses and dissertations. This service is provided by the Networked Digital Library of Theses and Dissertations.
    Our metadata is collected from universities around the world. If you manage a university/consortium/country archive and want to be added, details can be found on the NDLTD website.
1

Análise dos efeitos antiangiogênicos e antiproliferativos da halofuginona na leucemia promielocítica aguda / Analysis of the antiangiogenic and antiproliferative effects of halofuginone on acute promyelocytic leukemia

Assis, Patricia Aparecida de 03 August 2010 (has links)
Angiogênese é o termo utilizado para descrever o crescimento de novos vasos sanguíneos a partir dos já existentes. Vários estudos demonstraram a densidade microvascular (DMV) como um fator prognóstico nas leucemias, em particular, leucemia promielocítica aguda (LPA). Este subtipo de leucemia corresponde a cerca de 20 a 25% das leucemias mielóides agudas nos países latino-americanos e apresenta características clínicas, morfológicas e biológicas peculiares. A halofuginona (HF), originalmente descrita como um agente antifúngico apresenta capacidade de inibir o crescimento tumoral e formação de vasos em modelos animais de tumores sólidos. Estudos realizados por nosso grupo demonstraram que a HF inibiu a secreção do VEGF e a proliferação de linhagens celulares de LPA. Desta forma, o presente trabalho teve por objetivo determinar o potencial antiproliferativo e antiangiogênico da HF em um modelo experimental in vivo da LPA e avaliar os mecanismos subjacentes a sua ação. Primeiramente, a análise do ciclo celular em células NB4 tratadas com HF apresentou significativa diminuição da proliferação celular (2,093 ± 0,304 vs. 41,21 ± 3,25), juntamente com um aumento significativo da apoptose (12,53 ± 1,53 vs. 21,95 ± 0,79; p=0,0007). Por meio da técnica de Real Time Array foi possível identificar dois grupos de genes associados a apoptose celular diferencialmente expressos em células tratadas com HF: TNF, TNFRSF9, TNFTSF10B, CD40, FAS, CASP10, CASP8 e CASP3, sugerindo que a HF induz a via extrínseca de apoptose. A análise in vivo da HF foi realizada em camundongos NOD/SCID previamente irradiados e transplantados com células leucêmicas PML-RAR murinas. Camundongos tratados com HF, por 21 dias após o transplante não apresentaram remissão molecular, determinada pela amplificação do gene PML-RARA por PCR, porém foi observada menor infiltração leucêmica em relação aos camundongos não tratados (Leucócitos: 4,2 ± 3,89 vs. 20,6 ± 21,9; p<0.0001); Hemoglobina: 12,0 ± 1,40 vs. 9,6 ± 1,67; p<0.0001; e Plaquetas: 932,0 ± 122,5 vs. 552,0 ± 83,2; p<0.001 respectivamente) e um menor peso relativo do baço (0,006 vs. 0,012, p=0,0415). Ademais, a contagem diferencial e imunofenotipagem da medula óssea evidenciaram menor porcentagem de células mielóides imaturas (16,88 ± 6,27 vs. 44,06 ± 27,06). A HF também foi capaz de inibir a fosforilação de SMAD2 e consequentemente bloquear a via do TGF- em células NB4. No entanto, animais leucêmicos apresentaram menor nível sérico de TGF- em relação aos saudáveis e tratados (475,58 vs. 1.378,45/1.146,82 pg/mL; p<0,0001), sugerindo que o blasto leucêmico produz esta citocina e a diminuição de células leucêmicas resultou em diminuição dos níveis séricos de TGF-. A HF não aumentou a sobrevida dos animais leucêmicos e a elevação das enzimas hepáticas sugeriu que o tratamento foi hepatotóxico. Por fim, com relação à angiogênese, a análise da expressão gênica mostrou que o tratamento com HF inibiu a expressão de VEGF e EGF e o estudo por imunohistoquímica de seções da medula óssea evidenciou menor expressão VEGF (30 vs. 80%, p=0,0227), porém não houve diminuição da DMV. O conjunto desses resultados mostrou que a angiogênese é um importante alvo terapêutico na LPA, e que apesar da toxicidade, a HF apresenta potencial antileucêmico, tanto por conta de seus efeitos antiproliferativos e próapoptóticos, quanto por sua capacidade de inibir a produção de fatores próangiogênicos. / Angiogenesis is the term used to describe the growth of new blood vessels from the existing ones. Several studies have demonstrated the microvascular density (MVD) as a prognostic factor in leukemia, particularly acute promyelocytic leukemia (APL). This subtype of leukemia corresponds to 20-25% of acute myeloid leukemia in Latin America and presents clinical, morphological and biological peculiar characteristics. The halofuginone (HF) originally described as an antifungal agent has ability to inhibit tumor growth and vessel formation in animal models of solid tumors. Our group demonstrated that HF inhibits the VEGF secretion and cell proliferation in APL cell lineages. Thus, this study aimed to determine the antiproliferative and antiangiogenic potential of HF in an experimental model of APL in vivo and evaluate the mechanisms underlying its action. First, the cell cycle analysis in NB4 cells treated with HF showed a significant decrease in cell proliferation (2.093 ± 0.304 vs. 41.21 ± 3.25), along with a significant increase in apoptosis (12.53 ± 1.53 vs . 21.95 ± 0.79, p = 0.0007). Through Real Time Array it was possible to identify two groups of apoptosis associated genes differentially expressed in HF treated cells: TNF, TNFRSF9, TNFTSF10B, CD40, FAS, CASP10, CASP8 and CASP3, suggesting that HF induces apoptosis by extrinsic pathway. In vivo analysis of HF was performed in irradiated NOD/SCID mice transplanted with murine PML-RAR leukemic cells. Mice treated with HF for 21 days after transplantation showed no molecular remission as determined by amplification of PML-RARA gene by PCR, however minor leukemic infiltration was observed compared to untreated mice (leukocytes: 4.2 ± 3.89 vs . 20.6 ± 21.9, p <0.0001), hemoglobin: 12.0 ± 1.40 vs. 9.6 ± 1.67, p <0.0001, and Platelets: 932.0 ± 122.5 vs. 552.0 ± 83.2, p <0.001 respectively) and a lower relative weight of spleen (0.006 vs. 0.012, p = 0.0415). Furthermore, the differential count and immunophenotyping of bone marrow showed a lower percentage of immature myeloid cells (16.88 ± 6.27 vs. 44.06 ± 27.06). The HF was also able to inhibit the SMAD2 phosphorylation and consequently block the TGF- pathway in NB4 cells. However, leukemic animals presented lower serum TGF- compared to the healthy and treated (475.58 vs. 1378.45/1146.82 pg / mL, p <0.0001), suggesting that the leukemic blasts produces this cytokines and the decrease in leukemic cells resulted in decreased serum levels of TGF-. The HF did not increase the survival of leukemic animals and elevated liver enzymes suggested that the treatment was hepatotoxic. Finally, regarding angiogenesis, gene expression analysis showed that the HF treatment inhibited the expression of VEGF and EGF and the study by immunohistochemistry of sections of bone marrow showed less VEGF expression (30 vs. 80%, p = 0 0227), but there was no decrease in the MVD. Taken together, these results showed that angiogenesis is an important therapeutic target in APL, and despite the toxicity, HF has antileukemic potential, for both the antiproliferative and proapoptotic effects, and also for its ability to inhibit the production of proangiogenic factors.
2

Characterizing the Organization within Alternative Lengthening of Telomere Associated-promyelocytic Leukemia Nuclear Bodies

Larsen, Andrew 07 January 2011 (has links)
In the absence of telomerase activity, a subset of cancerous and immortalized cells maintain telomere length by means of a poorly understood mechanism, termed alternative lengthening of telomeres (ALT). Many details of telomere maintenance in ALT positive cells remain unclear, but significant evidence implicates a homologous recombination mechanism. ALT specific nuclear structures, known as ALT-associated promyelocytic leukemia nuclear bodies (APBs), are thought to serve as the site of telomere extension. Using electron spectroscopic imaging we have demonstrated that APBs contain substantial amounts of nucleic acid sequestered within the bodies. In contrast, promyelocytic leukemia nuclear bodies in non-ALT cell lines contain no significant nucleic acid. We show that the nucleic acid found in APBs is not RNA and provide evidence that it is in fact telomeric repeat DNA. This evidence supports a role for APBs to sequester extrachromosomal telomeric DNA in order to suppress the activation of DNA repair.
3

Characterizing the Organization within Alternative Lengthening of Telomere Associated-promyelocytic Leukemia Nuclear Bodies

Larsen, Andrew 07 January 2011 (has links)
In the absence of telomerase activity, a subset of cancerous and immortalized cells maintain telomere length by means of a poorly understood mechanism, termed alternative lengthening of telomeres (ALT). Many details of telomere maintenance in ALT positive cells remain unclear, but significant evidence implicates a homologous recombination mechanism. ALT specific nuclear structures, known as ALT-associated promyelocytic leukemia nuclear bodies (APBs), are thought to serve as the site of telomere extension. Using electron spectroscopic imaging we have demonstrated that APBs contain substantial amounts of nucleic acid sequestered within the bodies. In contrast, promyelocytic leukemia nuclear bodies in non-ALT cell lines contain no significant nucleic acid. We show that the nucleic acid found in APBs is not RNA and provide evidence that it is in fact telomeric repeat DNA. This evidence supports a role for APBs to sequester extrachromosomal telomeric DNA in order to suppress the activation of DNA repair.
4

Análise dos efeitos antiangiogênicos e antiproliferativos da halofuginona na leucemia promielocítica aguda / Analysis of the antiangiogenic and antiproliferative effects of halofuginone on acute promyelocytic leukemia

Patricia Aparecida de Assis 03 August 2010 (has links)
Angiogênese é o termo utilizado para descrever o crescimento de novos vasos sanguíneos a partir dos já existentes. Vários estudos demonstraram a densidade microvascular (DMV) como um fator prognóstico nas leucemias, em particular, leucemia promielocítica aguda (LPA). Este subtipo de leucemia corresponde a cerca de 20 a 25% das leucemias mielóides agudas nos países latino-americanos e apresenta características clínicas, morfológicas e biológicas peculiares. A halofuginona (HF), originalmente descrita como um agente antifúngico apresenta capacidade de inibir o crescimento tumoral e formação de vasos em modelos animais de tumores sólidos. Estudos realizados por nosso grupo demonstraram que a HF inibiu a secreção do VEGF e a proliferação de linhagens celulares de LPA. Desta forma, o presente trabalho teve por objetivo determinar o potencial antiproliferativo e antiangiogênico da HF em um modelo experimental in vivo da LPA e avaliar os mecanismos subjacentes a sua ação. Primeiramente, a análise do ciclo celular em células NB4 tratadas com HF apresentou significativa diminuição da proliferação celular (2,093 ± 0,304 vs. 41,21 ± 3,25), juntamente com um aumento significativo da apoptose (12,53 ± 1,53 vs. 21,95 ± 0,79; p=0,0007). Por meio da técnica de Real Time Array foi possível identificar dois grupos de genes associados a apoptose celular diferencialmente expressos em células tratadas com HF: TNF, TNFRSF9, TNFTSF10B, CD40, FAS, CASP10, CASP8 e CASP3, sugerindo que a HF induz a via extrínseca de apoptose. A análise in vivo da HF foi realizada em camundongos NOD/SCID previamente irradiados e transplantados com células leucêmicas PML-RAR murinas. Camundongos tratados com HF, por 21 dias após o transplante não apresentaram remissão molecular, determinada pela amplificação do gene PML-RARA por PCR, porém foi observada menor infiltração leucêmica em relação aos camundongos não tratados (Leucócitos: 4,2 ± 3,89 vs. 20,6 ± 21,9; p<0.0001); Hemoglobina: 12,0 ± 1,40 vs. 9,6 ± 1,67; p<0.0001; e Plaquetas: 932,0 ± 122,5 vs. 552,0 ± 83,2; p<0.001 respectivamente) e um menor peso relativo do baço (0,006 vs. 0,012, p=0,0415). Ademais, a contagem diferencial e imunofenotipagem da medula óssea evidenciaram menor porcentagem de células mielóides imaturas (16,88 ± 6,27 vs. 44,06 ± 27,06). A HF também foi capaz de inibir a fosforilação de SMAD2 e consequentemente bloquear a via do TGF- em células NB4. No entanto, animais leucêmicos apresentaram menor nível sérico de TGF- em relação aos saudáveis e tratados (475,58 vs. 1.378,45/1.146,82 pg/mL; p<0,0001), sugerindo que o blasto leucêmico produz esta citocina e a diminuição de células leucêmicas resultou em diminuição dos níveis séricos de TGF-. A HF não aumentou a sobrevida dos animais leucêmicos e a elevação das enzimas hepáticas sugeriu que o tratamento foi hepatotóxico. Por fim, com relação à angiogênese, a análise da expressão gênica mostrou que o tratamento com HF inibiu a expressão de VEGF e EGF e o estudo por imunohistoquímica de seções da medula óssea evidenciou menor expressão VEGF (30 vs. 80%, p=0,0227), porém não houve diminuição da DMV. O conjunto desses resultados mostrou que a angiogênese é um importante alvo terapêutico na LPA, e que apesar da toxicidade, a HF apresenta potencial antileucêmico, tanto por conta de seus efeitos antiproliferativos e próapoptóticos, quanto por sua capacidade de inibir a produção de fatores próangiogênicos. / Angiogenesis is the term used to describe the growth of new blood vessels from the existing ones. Several studies have demonstrated the microvascular density (MVD) as a prognostic factor in leukemia, particularly acute promyelocytic leukemia (APL). This subtype of leukemia corresponds to 20-25% of acute myeloid leukemia in Latin America and presents clinical, morphological and biological peculiar characteristics. The halofuginone (HF) originally described as an antifungal agent has ability to inhibit tumor growth and vessel formation in animal models of solid tumors. Our group demonstrated that HF inhibits the VEGF secretion and cell proliferation in APL cell lineages. Thus, this study aimed to determine the antiproliferative and antiangiogenic potential of HF in an experimental model of APL in vivo and evaluate the mechanisms underlying its action. First, the cell cycle analysis in NB4 cells treated with HF showed a significant decrease in cell proliferation (2.093 ± 0.304 vs. 41.21 ± 3.25), along with a significant increase in apoptosis (12.53 ± 1.53 vs . 21.95 ± 0.79, p = 0.0007). Through Real Time Array it was possible to identify two groups of apoptosis associated genes differentially expressed in HF treated cells: TNF, TNFRSF9, TNFTSF10B, CD40, FAS, CASP10, CASP8 and CASP3, suggesting that HF induces apoptosis by extrinsic pathway. In vivo analysis of HF was performed in irradiated NOD/SCID mice transplanted with murine PML-RAR leukemic cells. Mice treated with HF for 21 days after transplantation showed no molecular remission as determined by amplification of PML-RARA gene by PCR, however minor leukemic infiltration was observed compared to untreated mice (leukocytes: 4.2 ± 3.89 vs . 20.6 ± 21.9, p <0.0001), hemoglobin: 12.0 ± 1.40 vs. 9.6 ± 1.67, p <0.0001, and Platelets: 932.0 ± 122.5 vs. 552.0 ± 83.2, p <0.001 respectively) and a lower relative weight of spleen (0.006 vs. 0.012, p = 0.0415). Furthermore, the differential count and immunophenotyping of bone marrow showed a lower percentage of immature myeloid cells (16.88 ± 6.27 vs. 44.06 ± 27.06). The HF was also able to inhibit the SMAD2 phosphorylation and consequently block the TGF- pathway in NB4 cells. However, leukemic animals presented lower serum TGF- compared to the healthy and treated (475.58 vs. 1378.45/1146.82 pg / mL, p <0.0001), suggesting that the leukemic blasts produces this cytokines and the decrease in leukemic cells resulted in decreased serum levels of TGF-. The HF did not increase the survival of leukemic animals and elevated liver enzymes suggested that the treatment was hepatotoxic. Finally, regarding angiogenesis, gene expression analysis showed that the HF treatment inhibited the expression of VEGF and EGF and the study by immunohistochemistry of sections of bone marrow showed less VEGF expression (30 vs. 80%, p = 0 0227), but there was no decrease in the MVD. Taken together, these results showed that angiogenesis is an important therapeutic target in APL, and despite the toxicity, HF has antileukemic potential, for both the antiproliferative and proapoptotic effects, and also for its ability to inhibit the production of proangiogenic factors.
5

A Rare Case of Acute Promyelocytic Leukemia in Pregnancy

Franklyn, Lindsey, Mhadgut, Hemendra, Sinha, Alok, Singal, Sakshi 28 April 2020 (has links)
Acute promyelocytic leukemia (APL) is a clinically distinct and rare type of acute myeloid leukemia and represents an oncologic emergency. Even rarer is the incidence of APL in pregnancy with less than 60 cases described in the literature. A 33-year-old pregnant female at 34 week gestation presented to hospital with reports of abdominal pain. On admission she was found to have acute onset pancytopenia with a WBC count of 1.2, Hemoglobin of 9.7g/dl, and platelet count of 26000. Initial history, exam, and investigations including a peripheral smear, coagulation panel, liver function, vitamin b12 and folate levels did not reveal possible etiology of pancytopenia. Given worsening pancytopenia, bone marrow biopsy was done which showed 58% promyelocytes and 11% blasts with numerous Auer rods present. Cytogenetics showed abnormal female karyotype with t(15:17) and FISH analysis revealed PML/RARA fusion in 76.5% of analyzed cells. The above findings were diagnostic of APL. After multidisciplinary discussion with high risk obstetrics physician, it was decided to immediately induce labor for immediate initiation of treatment of APL. She had a prolonged labor requiring aggressive blood product support and initiation of All trans retinoic acid (ATRA) before delivery given concerns of coagulopathy. Induction treatment with Arsenic trioxide (ATO) was started the day after her delivery. Repeat bone marrow biopsy on day 24 showed complete morphologic remission. Shortly thereafter, she started cycle 1 of consolidation with ATRA and arsenic trioxide. APL is characterized by a translocation between chromosome 15 and 17. Coagulopathy is a pathognomonic feature of this leukemia and often the reason for high mortality in early course of disease. APL when treated with ATRA and ATO, has excellent remission rate and 99% overall survival at 2 years. APL in pregnancy is associated with increased risk of preterm delivery, perinatal mortality, and miscarriage. Following pregnancy, there is an increased risk of bleeding, infection, or placental abruption. ATRA, one of the pillars around which treatment of APL revolves, is highly teratogenic during the first trimester and has low risk later in pregnancy. Treatment is directed by the trimester of pregnancy. Termination of pregnancy or treatment with single agent conventional chemotherapy is preferred in the first trimester whereas treatment with ATRA prior to delivery and use of chemotherapy after delivery is the preferred approach in the 2nd and 3rd trimester. This case is an example of individualized approach with a multidisciplinary team need in the setting of scarce data.
6

Regulation of Prelamin a Endoprotease Activity by Prelamin A

Kilic, Fusun, Salas-Marco, Joe, Garland, John, Sinensky, Michael 01 September 1997 (has links)
The maturation of lamin A is completed by the endoproteolytic cleavage of its farnesylated precursor protein, prelamin A. In the absence of this cleavage, prelamin A can neither give rise to lamin A nor assemble into the nuclear lamina. We call the enzyme which catalyzes this endoproteolytic step the 'prelamin A endoprotease'. In this study, we begin characterization of the regulation of prelamin A endoprotease. In particular, we address the question as to whether prelamin A endoprotease activity is constitutive in cells or responds to expression of prelamin A. To do this, we compared the activity of this novel endoprotease in cells which express prelamin A with those that do not. Our data shows that the enzymatic activity of prelamin A endoprotease is enhanced by the expression of prelamin A.
7

WT1 et régulation de hTERT : cas du neuroblastome et de la leucémie aiguë promyélocytaire / WT1 and hTERT in Neuroblastoma and in Acute Promyelocytic Leukemia

Masserot, Caroline 09 December 2014 (has links)
La télomérase, enzyme qui permet le maintien de la longueur des télomères est activée dans la majorité des cellules cancéreuses. Du fait de son rôle dans l’immortalité cellulaire, elle a été proposée comme cible de nouvelles stratégies anticancéreuses; il est donc fondamental d’identifier les mécanismes de sa régulation. Des travaux récents du laboratoire ont démontré, en utilisant une lignée de leucémie aiguë promyélocytaire résistante à la différenciation par les rétinoïdes (NB4-LR1), que l’acide rétinoïque tout trans (ATRA) induit une répression transcriptionnelle de hTERT, sous-unité catalytique de la télomérase, indépendamment de la différenciation. Cette répression est également associée à la mort des clones résistants. Il a également été montré lors du traitement par l’ATRA de cellules résistantes à cette répression, NB4-LR1SFD, qu’il existait une hyperméthylation de la région distale du promoteur de hTERT associée à la persistance de sa transcription et à la prolifération cellulaire. Ceci nous a conduit à proposer un modèle de régulation de hTERT dans lequel l'induction de modifications épigénétiques de la région distale de son promoteur empêcherait la fixation d'éventuels répresseurs. Des résultats récents suggèrent que WT1, facteur connu pour contribuer à la répression de hTERT, pourrait être un de ces facteurs. WT1 code pour un facteur de transcription à doigt de zinc et a été décrit pour la première fois comme délété dans les tumeurs de Wilms (tumeurs rénales de l’enfant). Cependant le rôle de WT1 dans développement tumoral varie en fonction des modèles cellulaires ; il peut avoir un rôle d’oncogène ou au contraire agir comme un gène suppresseur de tumeur. Dans le but d’élucider les mécanismes de régulation de la télomérase, nous avons donc voulu étudier le rôle de WT1 dans la répression de hTERT. Pour ce travail, nous avons utilisé deux modèles cellulaires :• La Leucémie aigue promyélocytaire (LAP) : leucémie aigue myéloblastique caractérisée par un transcrit de fusion impliquant le récepteur aux rétinoïdes.• Le neuroblastome : tumeur solide extra crânienne la plus fréquente chez l’enfant. Cette maladie est très hétérogène aussi bien au niveau biologique que clinique ; en effet certaines formes peuvent régresser spontanément alors que d’autres, très agressives, sont résistantes à toutes les thérapeutiques actuelles. Cette hétérogénéité clinique est notamment liée à la différenciation de la tumeur et également à la présence ou non de l’amplification de l’oncogène N-Myc qui a un rôle pronostic majeur dans cette maladie. Les voies de signalisations impliquées dans le fort pouvoir tumorigène des neuroblastomes ne sont pas encore clairement identifiées.Nous avons pu montrer dans ces modèles que WT1 réprime hTERT et que cette répression semble fonction de l'état de méthylation de la région distale du promoteur de hTERTLa 2ème partie de mon travail a été d’étudier le rôle de WT1 dans les neuroblastomes. Les résultats de nos travaux montrent que WT1 est plus exprimé dans les tumeurs sans amplification de N-Myc et dont la différenciation est stromale. Cependant la surexpression de WT1 dans des tumeurs sans amplification de N-Myc semble associée à un moins bon pronostic. L’étude de l’expression de WT1 pourrait constituer un outil pronostic intéressant dans ces tumeurs. / Telomerase is expressed and active in most immortalized cells. Whereas telomerase becomes activated during neoplastic transformation, its activity decreases during differentiation of various immortal cells in response to pharmacological agents, including retinoids. We showed using both an Acute Promyelocytic Leukemia (APL) cellular model (NB4 cell model) and Neuroblastoma cells that all-trans-retinoic acid (ATRA) induced a transcriptional repression of the catalytic subunit of telomerase, hTERT, associated with differentiation. This repression also occurred independently of differentiation, as demonstrated during long term treatment of ATRA-induced maturation resistant NB4-LR1, leading to telomere shortening, growth arrest and cell death. Changes in chromatin environment of hTERT promoter and binding of transcriptional factors have been demonstrated in differentiating cells when hTERT is repressed. However, it is not clear whether these changes are directly involved in hTERT repression or only linked to differentiation. A variant cell line was isolated from NB4-LR1 cells, (NB4-LR1SFD), which bypassed the death step because of a re-activated telomerase and resisted to hTERT repression despite the continuous presence of ATRA. Using both NB4-LR1 and NB4-LR1SFD cells, it was shown that the mechanisms of ATRA-induced hTERT repression involved: 1) a switch from c-myc to mad1 binding at the proximal domain of hTERT promoter, 2) epigenetic modifications of the distal domain of hTERT promoter (-600 -250 nucleotides). Indeed, the persistence of hTERT transcription was associated with an hypermethylation of the distal domain in ATRA-treated NB4-LR1SFD. Interestingly, the binding of a known hTERT repressor, WT1, to this distal domain, was defective in NB4-LR1SFD. The first part of my thesis was to investigate the role in hTERT transcriptionnal regulation of both c-myc and WT1, two transcription factors, which bind to the proximal and the distal region of hTERT promoter, respectively. The second part was to determine the role of WT1 in neuroblastoma. Neuroblastoma is the most common extra cranial solid tumor in childhood and the most frequently diagnosed neoplasm during the infancy. A striking feature of this tumor is its clinical heterogeneity. Among tumor progression markers delineated so far, MYCN amplification occurs in about 25% of total neuroblastoma cases and this percentage increases at 30% in advanced stage NEUROBLASTOMA. Despite the fact that MYCN amplification is strongly correlated with neuroblastoma of poor outcome, MYCN status cannot predict all cases of poor survival in neuroblastoma. In addition, neuroblastoma without MYCN amplification (about 70-80% of neuroblastoma) are far to display favorable behavior. WT1 was initially identified as a tumor suppressor gene involved in the development of a pediatric renal tumor (Wilm’s tumor). Here, we describe an inverse correlation between WT1 expression and MYCN amplification and expression. However and most notably, our results show that WT1 gene expression is associated with a poor outcome for patients showing non-MYCN-amplified tumors. Thus WT1 expression may be a prognostic marker for a better risk-stratification and for an optimized therapeutic management of neuroblastoma.
8

Identification of new regulators for PML nuclear bodies / Identification de nouveaux régulateurs des corps nucléaires PML

Snollaerts, Thibaut 28 September 2016 (has links)
La protéine Promyelocytic Leukemia (PML) est impliquée dans de nombreux processus cellulaires, et identifiée comme un suppresseur de tumeur. Cette protéine est le composant structural des Corps Nucléaires PML (CNs-PML) dont l'intégrité, compromise dans certaines leucémies, dépend strictement de sa SUMOylation. Ce projet de thèse visait à identifier de nouveaux régulateurs des CNs-PML, et par extension de la voie SUMO, en utilisant comme 'read-out' l'anatomie des CNs-PML, laquelle est extrêmement sensible au niveau de SUMOylation cellulaire globale. Ces travaux sont basés sur un criblage siARNs à grande échelle qui a conduit à l'identification de deux candidats SKP1et RBX1, tous deux faisant partie intégrante d'un complexe d'ubiquitine E3 ligase appelé " SKP1-CUL1-F-Box containing complex " (SCF). Nous avons pu démontrer l'implication de SKP1 et RBX1 dans la stabilité de la protéine PML avec des expériences de gain et perte de fonction. Nous avons également identifié FBXO9 comme la protéine F-Box capable de reconnaitre spécifiquement PML, causant son ubiquitination par le complexe SCFFBXO9, suivie de sa dégradation par le protéasome. En revanche, le site d'interaction de FBXO9 sur PML -tout comme la kinase impliquée dans ce processus de reconnaissance- restent encore à identifier. PML étant dégradé dans de nombreux cancers, il apparait essentiel d'avoir une meilleure compréhension des mécanismes post-traductionnels menant à sa dégradation. Ces travaux devraient à long terme permettre de révéler de nouveaux régulateurs des CNs-PML, et potentiellement permettre le développement de nouvelles stratégies thérapeutiques, visant à moduler les CNs-PML dans la cellule tumorale. / ProMyelocytic Leukemia (PML) protein is implicated in a number of key cellular processes, and was identified as a tumor suppressor. This protein is one of the main structural components forming the PML Nuclear Bodies (PML-NBs) whose integrity -compromised in some leukemias- is strictly dependent on PML SUMOylation. The goal of this thesis project was to identify new regulators of PML Nuclear Bodies, and by extension of the SUMO pathway, using PML-NBs, which are extremely sensitive to global cellular SUMOylation level, as a read out. This work is based on a high throughput siRNA screen, which led to the identification of two proteins, SKP1a and RBX1, which are both part of an Ubiquitin E3 ligase complex called SKP-Cullin-F-Box containing complex (SCF). We were able to show the involvement of SKP1 and RBX1 in PML protein stability through gain and loss of function experiments. We also identified FBXO9 as the F-Box capable of specifically recognizing PML, causing its ubiquitination by SCFFBXO9 complex and subsequent degradation by the proteasome. However, FBXO9 site of interaction on PML and the identity of the kinase implicated in this recognition processes are yet to be discovered. PML being degraded in numerous cancers, it is essential to acquire a better understanding of post-translational mechanism leading to the degradation of this tumour suppressor. In the long term, this work should, allow the discovery of new PML Nuclear Body regulators and potentially allow the development of new strategies aiming to modulate PML Nuclear Bodies in tumoral cells.
9

Régulation de la télomérase dans un modèle de leucémie aigue promyélocytaire : rôle de l'ARN long non codant H19 / Regulation of telomerase in a model of acute promyelocytic leukemia : role of the long non coding RNA H19

El hajj, Joelle 17 May 2018 (has links)
Le couple télomère/télomérase apparaît comme une cible prometteuse pour de potentiels agents anticancéreux qui seraient actifs sur un large éventail de tumeurs. Le laboratoire d’accueil a montré dans un modèle de leucémie aiguë promyélocytaire (LAP), qu'un agent utilisé en clinique, l'acide rétinoïque (ATRA), exerce une activité anti-tumorale en réprimant la transcription de la sous-unité catalytique hTERT indépendamment de la différenciation. Ce modèle (NB4) avec ses variants cellulaires résistant (NB4-LR1SFD) ou non à la répression de hTERT (NB4-LR1) par l’ATRA constitue un outil de choix pour l’identification de facteurs régulateurs de hTERT et la recherche des bases moléculaires de sa réactivation.Une approche transcriptomique a été utilisée afin d’identifier de nouveaux gènes et/ou réseaux de signalisation induits par l’ATRA et régulateurs de hTERT. L’analyse bioinformatique nous a permis de construire des profils d’expression différentielle entre les 2 lignées et des réseaux d’interaction. Parmi les candidats, H19, un ARN long de 2.5Kb, polyadénylé et non codant. H19 est classé parmi les gènes supresseurs de tumeurs : en son absence il y a développement de cancer (cas de la tumeur de Wilms, rhabdomyosarcome embryonnaire, Syndrome Beekwith-Wiedman) ; sa réintroduction par transfection conduit à une perte de tumoriginicité. Cependant H19 est reconnu de plus en plus comme un oncogène vu que son expression est élevée dans plusieurs types de cancers solides. Par contre peu d’études s’intéressent au rôle de H19 dans les leucémies, d’où notre intérêt pour l’étudier dans le modèle LAP que nous avons développé.Nous avons mis au point la mesure d’expression de H19 par RT-PCR quantitative, validé les données obtenues dans l’analyse transcriptomique et montré que le traitement ATRA induit l’expression de H19 dans les cellules NB4-LR1 alors que cette expression est plutôt diminuée dans les cellules NB4-LR1SFD. L’induction observée dans les cellules NB4-LR1 existe indépendamment de la différenciation. Par contre, cette induction peut être observée associée à la différenciation ou à l’apoptose dans la lignée cellulaire NB4-LR1SFD parallèlement à une diminution importante de l’expression de hTERT. Ce résultat important montre que la lignée NB4-LR1SFD ne présente pas de défaut général d’induction de H19. Ces données suggèrent l’existence d’une corrélation inverse entre le niveau d’expression de hTERT et celui de H19 dans ce modèle cellulaire. De façon importante, l’analyse des banques de données issues de patients LAP publiquement accessibles retrouve cette corrélation inverse.Une diminution d’activité télomérasique est observée dans des extraits cellulaires incubés en présence de l’ARN H19 transcrit in vitro. Cette diminution d’activité est observée aussi après surexpression de H19 in cellulo. Les expériences de RIP (RNA immunoprecipitation) ont montré une diminution de la quantité de hTR lié à hTERT suite à une augmentation d’expression de H19 après traitement ATRA in vitro ou après surexpression de H19 in cellulo. Une hypothèse serait que H19 induirait un déplacement de hTR du complexe hTR-hTERT. Cependant, les expériences de « pull-down » n’ont pas réussi à confirmer l’hypothèse d’une interaction possible entre l’ARN H19 et la protéine TERT.Mon travail de thèse identifie pour la première fois H19, un ARN long non codant, comme facteur régulateur potentiel de hTERT pouvant modifier son activité. Ce travail proposerait non seulement un mécanisme nouveau de régulation de l’activité télomérase mais aussi une fonction nouvelle pour H19 dans ce type de cancer. / The telomere / telomerase pair appears to be a promising target for potential anticancer agents that would be active on a wide range of tumors. The host laboratory has shown in a model of acute promyelocytic leukemia (APL), that a clinically used agent, retinoic acid (ATRA), exerts anti-tumor activity by repressing the transcription of the catalytic subunit hTERT regardless of differentiation. This model (NB4) with its resistant cell variants (NB4-LR1SFD) or not to the repression of hTERT (NB4-LR1) by ATRA is a tool of choice for the identification of hTERT regulatory factors and the search for molecular bases of its reactivation.A "microarray" approach has been used to identify new ATRA-mediated genes and / or signaling networks and potential hTERT regulators. Bioinformatic analysis allowed us to build differential expression profiles between the 2 lineages and interaction networks. Among the candidates, H19, a 2.5Kb long, polyadenylated and non-coding RNA. H19 is classified as a tumor suppressor gene: in its absence there is cancer development (case of Wilms tumor, embryonic rhabdomyosarcoma, Beckwith-Wiedman syndrome); its reintroduction by transfection leads to a loss of tumorigenicity. However H19 is increasingly recognized as an oncogene as its expression is elevated in several types of solid cancers. However, few studies are interested in the role of H19 in leukemias, hence our interest in studying it in the APL model that we have developed.We developed the H19 expression measurement by quantitative RT-PCR, validated the data obtained in the "microarray" analysis and showed that the ATRA treatment induces the expression of H19 in NB4-LR1 cells whereas this expression is rather diminished in NB4-LR1SFD cells. The induction observed in NB4-LR1 cells exists independently of differentiation. On the other hand, this induction can be observed associated with the differentiation or apoptosis in the NB4-LR1SFD cell line in parallel with a significant decrease in the expression of hTERT. This important result shows that the NB4-LR1SFD line does not have a general H19 induction defect. These data suggest the existence of an inverse correlation between the expression level of hTERT and that of H19 in this cellular model. Importantly, the analysis of publicly accessible APL patients’ databases finds this inverse correlation as well.We observed a decrease in telomerase activity in cellular extracts incubated in the presence of in vitro transcribed H19 RNA. This decrease in activity was also observed after overexpression of H19 in cellulo. The RIP (RNA immunoprecipitation) experiments showed a decrease in hTR amount bound to hTERT following an increase in H19 expression after ATRA treatment in vitro or after overexpression of H19 in cellulo. We hypothesize that H19 induces a displacement of hTR from the hTR-hTERT complex. However, the "pull-down" experiments failed to confirm the hypothesis of a possible interaction between H19 RNA and TERT protein.My thesis work identifies, for the first time, the long non-coding RNA H19, as a potential regulator of hTERT that can modify its activity. This work would propose not only a new mechanism of regulation of telomerase activity but also a new function for H19 in this type of cancer.
10

Biochemical, Cytotoxic And Genotoxic Effects Of Aescin On Human Lymphocytes And Hl-60 Promyeloid Leukemia Cell Line

Topsoy Kolukisa, Serap 01 July 2005 (has links) (PDF)
Aescin is a mixture of several acidic triterpenoid saponin glycosides found in the extracts of the horse chestnut tree. Horse chestnut, Aesculus Hipoocastanum, is one of the 25 domestic species of Aesculus that are mostly large, ornamental shade trees. Although known to be poisonous, the nuts of the horse chestnut are used by Amerindians, after detoxification. Horse chestnuts are said to have several traditional medicinal usages including even cancer. In this study the biochemical, genotoxic, and cytotoxic effects of aescin was studied using isolated lymphocytes, whole blood lymphocytes and HL-60 promyeloid leukemia cell lines. Cytotoxicity of aescin was examined by trypan blue viability staining of the cells in culture treated with varying aescin concentrations. It was observed that aescin was cytotoxic at all concentrations, for all cell types studied, except whole blood lymphocytes, where it was not cytotoxic at 10-9 and 10-10 M concentrations. Genotoxicity of aescin was examined by sister chromatid exchange and micronucleus. The genotoxic effect of Aescin was observed to be more significant over isolated lymphocytes compared to other cell lines. On the otherhand, aescin at 10-8 M and lower concentrations were observed to be non-genotoxic over whole blood lymphocytes whereas this concentration was considerably toxic for isolated lymphocytes and for HL-60 cell lines. Apoptotic properties of aescin were determined by DNA fragmentation, cytochrome c release and negative NAPO staining. All the Aescin concentrations tested resulted in apoptosis over HL-60 cell lines, whereas necrosis was not observed. However, isolated lymphocytes showed both apoptosis and necrosis upon treatment with 10-6 M to 10-8 M aescin, exhibiting apoptosis only at 10-9 M and 10-10 M. Biochemical effects of aescin were investigated by following GST and NAT enzyme activities. An increase in GST enzyme activity was observed over all cell lines treated with increasing aescin concentrations for 72 hours. Whereas NAT activity was decreased upon treatment with aescin in similar manner.

Page generated in 0.1458 seconds